department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Camzyos · pharmadog

pharmadog
drugs
Camzyos

drug

patient view →

mavacamten

Marketedupdated 2mo ago

by Bristol-Myers Squibb Co

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Camzyos

generic

mavacamten

indication

Hypertrophic Cardiomyopathy

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Apr 28, 2027

295 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (8)

Apr 28, 2036compositionUS RE50050
Apr 28, 2036compositionUS RE50050
Apr 28, 2036compositionUS RE50050
Apr 28, 2036compositionUS RE50050
Jun 19, 2034method-of-use (U-3373)US 9585883
Jun 19, 2034method-of-use (U-3373)US 9585883
Jun 19, 2034method-of-use (U-3373)US 9585883
Jun 19, 2034method-of-use (U-3373)US 9585883

FDA exclusivities (12)

Apr 28, 2029ODE-398Orphan Drug (7y)2.8y
Apr 28, 2029ODE-398Orphan Drug (7y)2.8y
Apr 28, 2029ODE-398Orphan Drug (7y)2.8y
Apr 28, 2029ODE-398Orphan Drug (7y)2.8y
Apr 28, 2027NCENew Chemical Entity (5y)295d
Apr 28, 2027NCENew Chemical Entity (5y)295d

Apr 28, 2027NCENew Chemical Entity (5y)295d

Apr 28, 2027NCENew Chemical Entity (5y)295d

Jun 15, 2026M-297Method (3y)

Jun 15, 2026M-297Method (3y)

Jun 15, 2026M-297Method (3y)

Jun 15, 2026M-297Method (3y)

Trials studying mavacamten

—A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in Chinarecruitingn=500
—COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)active not recruitingn=331
—Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)recruitingn=36
phase4A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)recruitingn=50
phase3A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCMcompletedn=314
—Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japanrecruitingn=200
phase3A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathycompletedn=38
phase3A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathyactive not recruitingn=44

more trials →